Iron Overload Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Iron Overload indicates a physical
condition resulting in increased total body iron stores, with or without organ
dysfunction. In other words, it refers to a cluster of genetic or acquired
conditions that result in the extra accumulation of iron in the body. Since
excess iron is toxic to the cells, its collection can lead to permanent tissue
damage, resulting in organ failure if left untreated for a prolonged period.
Iron Overload is caused by an inherited disorder called hereditary
hemochromatosis (HH) or is acquired in patients with certain conditions that
need frequent blood transfusions. Iron homeostasis depends on a complex feedback
mechanism between body iron requirements and intestinal absorption. Humans lack
a physiological mechanism for the excretion of excess iron. The hormone
hepcidin, a 25-amino acid peptide, is produced mainly in the liver and secreted
into the blood and is now recognized as the critical regulator of iron
homeostasis. Any disruptions in the regulation of hepcidin are a cause of many
disorders related to iron homeostasis. Iron overload syndromes are broadly
divided into inherited or Primary iron overload called hereditary
hemochromatosis (HH) and Secondary iron overload syndromes. The former is a
genetic disorder that causes the body to absorb excessive iron from the diet.
The most common subtype of the above is HFE related HH caused by mutations in
the human hemochromatosis gene (HFE). The HFE protein regulates the absorption
of iron by controlling hepcidin production.
- The prevalence of primary and secondary iron overload
syndromes cases varies from 325 to 385 cases per 100,000 population in the
USA.
Thelansis’s “Iron Overload Disorder Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Iron
Overload Disorder treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Iron Overload Disorder across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Iron Overload Disorder Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment